Sign In
Buy MBOT
$1.72
-0.0200 (-1.15%)
At Close: Jul 31, 2026
Microbot Medical® Bolsters Commercial Leadership Team with the Addition of Experienced Healthcare Officers
08:30am, Wednesday, 23'rd Apr 2025
The addition of a seasoned VP of Marketing compliments the recent hiring of the Company's VP of Sales to establish its commercialization readiness infrastructure
Successful robotic navigation was achieved in every case and met the primary endpoint of the study LIBERTY ® showed a 92% reduction in radiation exposure with no adverse events reported HINGHAM, Ma
Company Reaffirms Expected Timing of FDA Decision With Respect to 510(K) Clearance of LIBERTY® During the Current Second Quarter Company Reaffirms Expected Timing of FDA Decision With Respect to 510(
Mr. Paul Mullen Most Recently Served as the Director of Sales at Inari Medical which was Acquired by Stryker Corporation Earlier This Year
BRAINTREE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced its collaboration with Core
Microbot Medical Closes $13 Million Registered Direct Offering
06:15pm, Tuesday, 11'th Feb 2025
BRAINTREE, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under N
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
08:00am, Monday, 10'th Feb 2025
BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 6,103,289 shares of
Microbot Medical Closes $8.6 Million Registered Direct Offering
10:25am, Friday, 10'th Jan 2025
BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under N
HINGHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nas
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
08:30am, Monday, 30'th Dec 2024
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025 Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025
MBOT Stock Gains Following FDA Submission of the LIBERTY System
12:56pm, Thursday, 12'th Dec 2024
Microbot Medical announces the submission of its LIBERTY System for FDA marketing clearance.
Microbot Medical® CEO Harel Gadot to Discuss Endovascular Robotics on Benzinga All Access
10:18am, Tuesday, 10'th Dec 2024
Livestream Interview Can be Viewed Today at 10:50am ET at Benzinga All Access Live
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
01:25pm, Wednesday, 16'th Oct 2024
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
U.S. Food and Drug Administration (FDA) Submission Expected by end of 2024 Clinical Data to be Presented at Medical Conference in Early 2025 BRAINTREE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Microbo
Confirms the Company on Track for FDA 510(k) Submission by end of 2024 Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study BRAINTREE, Mass., Sept. 30
